" class="no-js "lang="en-US"> Meindert Boysen - Medtech Alert
Sunday, July 27, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Meindert Boysen

Meindert Boysen

About Meindert Boysen

After qualifying as a pharmacist, Meindert worked in a hospital in the Netherlands and held positions in health outcomes and sales in the pharmaceutical industry.

He completed an MSc in Health Policy Planning and Financing at the London School of Hygiene and Tropical Medicine and the London School of Economics and Political Sciences and briefly worked for the King’s Fund before starting at NICE in 2004.

Meindert was previously on the board of directors for the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), from 2017 to 2020.

Related Story

Diseases

 First Treatment Approved in England for Advanced Bile Duct Cancer | Pharmtech Focus

First Treatment Approved in England for Advanced Bile Duct Cancer

July 22 2021

The drug pemigatinib (Pemazyre) will now be an option for people with a rare type of bile […]